ANI Pharmaceuticals (ANIP) PT Lowered to $30 at Cantor Fitzgerald, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ANIP Hot Sheet
Price: $72.28 +2.28%
Rating Summary:
9 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 1
Rating Summary:
9 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 1
Join SI Premium – FREE
Cantor Fitzgerald analyst Brandon Folkes lowered the price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $30.00 (from $40.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Raised to $52 at BofA Securities
- ProsiebenSat.1 Media SE (PSM:GR) (PBSFY) PT Lowered to EUR5.40 at JPMorgan
- The Magnum Ice Cream Company (MICC:NA) (MICC) PT Raised to EUR16 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Cantor Fitzgerald, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
